<DOC>
	<DOCNO>NCT02630875</DOCNO>
	<brief_summary>This study evaluate A4250 ( IBATinhibitor ) treatment option pediatric patient chronic cholestasis main emphasis safety evaluation effect pruritus</brief_summary>
	<brief_title>A4250 , IBAT Inhibitor Pediatric Cholestasis</brief_title>
	<detailed_description>The primary aim Phase II exploratory study patient treat A4250 due cholestasis induce pruritus : - Assess safety tolerability A4250 , orally administer first single dose four week treatment period , determine occurrence treatment-emergent SAEs - Explore change serum total bile acid four week treatment period Secondary safety aim include assessment safety tolerability A4250 , orally administer first single dose four week treatment period , determine occurrence treatment-emergent AEs change safety parameter include laboratory test vital sign Secondary efficacy aim : - Demonstrate efficacy A4250 , orally administer four week treatment period , liver biochemistry variable pruritus parameter - Evaluate pharmacokinetic property A4250 orally administer first single dose four week treatment period - Evaluate change VAS-itching score four week treatment period</detailed_description>
	<mesh_term>Cholestasis</mesh_term>
	<criteria>Diagnosis pruritus due chronic cholestasis base history investigator judgment . This include restrict patient Progressive familial intrahepatic cholestasis ( PFIC ) , Alagille syndrome ( ALGS ) , Biliary Atresia Sclerosing Cholangitis Any condition opinion investigator constitute risk patient contraindication participation completion study , could interfere study objective , conduct , evaluation Clinical biochemical sign decompensated liver disease Liver transplantation</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>